CN106866624A - 一种卡比替尼的化学合成方法 - Google Patents
一种卡比替尼的化学合成方法 Download PDFInfo
- Publication number
- CN106866624A CN106866624A CN201710105737.3A CN201710105737A CN106866624A CN 106866624 A CN106866624 A CN 106866624A CN 201710105737 A CN201710105737 A CN 201710105737A CN 106866624 A CN106866624 A CN 106866624A
- Authority
- CN
- China
- Prior art keywords
- buddhist nun
- compound
- chemical synthesis
- synthesis process
- card according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 36
- 238000006243 chemical reaction Methods 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 238000011938 amidation process Methods 0.000 claims abstract description 4
- 238000010511 deprotection reaction Methods 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 23
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 239000012044 organic layer Substances 0.000 claims description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- 229940125782 compound 2 Drugs 0.000 claims description 12
- PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 claims description 12
- 229910052723 transition metal Inorganic materials 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- 229940126214 compound 3 Drugs 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 9
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 9
- 238000004440 column chromatography Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 235000002639 sodium chloride Nutrition 0.000 claims description 8
- -1 transition metal salt Chemical class 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 7
- 150000007530 organic bases Chemical class 0.000 claims description 7
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 6
- 230000005494 condensation Effects 0.000 claims description 6
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 6
- 150000003624 transition metals Chemical class 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229940125904 compound 1 Drugs 0.000 claims description 5
- DBMRSXHNJMWYGQ-UHFFFAOYSA-N n-fluoro-4-iodoaniline Chemical class FNC1=CC=C(I)C=C1 DBMRSXHNJMWYGQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000005292 vacuum distillation Methods 0.000 claims description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052772 Samarium Inorganic materials 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 4
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 3
- 230000000171 quenching effect Effects 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052779 Neodymium Inorganic materials 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- ZLWLTDZLUVBSRJ-UHFFFAOYSA-K chembl2360149 Chemical compound [Na+].[Na+].[Na+].O=C1C(N=NC=2C=CC(=CC=2)S([O-])(=O)=O)=C(C(=O)[O-])NN1C1=CC=C(S([O-])(=O)=O)C=C1 ZLWLTDZLUVBSRJ-UHFFFAOYSA-K 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 229910052738 indium Inorganic materials 0.000 claims description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 2
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 150000003053 piperidines Chemical class 0.000 claims description 2
- 229910052718 tin Inorganic materials 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 claims 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims 1
- 239000001119 stannous chloride Substances 0.000 claims 1
- 235000011150 stannous chloride Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 19
- 239000000463 material Substances 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- 230000000977 initiatory effect Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 2
- 238000006467 substitution reaction Methods 0.000 abstract description 2
- YJPHJYYUYIEGIG-UHFFFAOYSA-N FCC1=C(C#N)C=CC(=C1CF)CF Chemical compound FCC1=C(C#N)C=CC(=C1CF)CF YJPHJYYUYIEGIG-UHFFFAOYSA-N 0.000 abstract 1
- 238000007259 addition reaction Methods 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000005457 optimization Methods 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- WJFTZTWFUUOBLV-UHFFFAOYSA-N 2-(azetidin-3-yl)piperidine Chemical class C1NCC1C1NCCCC1 WJFTZTWFUUOBLV-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 238000003747 Grignard reaction Methods 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 2
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- DRNJIKRLQJRKMM-UHFFFAOYSA-N 4-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=C(C#N)C=C1 DRNJIKRLQJRKMM-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WGNZRLMOMHJUSP-UHFFFAOYSA-N benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 WGNZRLMOMHJUSP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- RHFUXPCCELGMFC-UHFFFAOYSA-N n-(6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl)-n-phenylmethoxyacetamide Chemical compound OC1C(C)(C)OC2=CC=C(C#N)C=C2C1N(C(=O)C)OCC1=CC=CC=C1 RHFUXPCCELGMFC-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
本发明属于化学合成领域,具体涉及一种卡比替尼的制备方法。该方法以2,3,4‑三氟苯甲酸苄酯为起始原料,通过取代反应、脱保护反应、酰胺化反应、催化加成反应等步骤得到卡比替尼。该方法原料价廉易得,工艺路线段,工反应过程易于操作,收率高,且环境友好,适合工业化大批量生产。
Description
技术领域
本发明属于化学合成领域,具体涉及一种抗肿瘤药卡比替尼的化学合成方法。
背景技术
黑色素瘤,又称恶性黑色素瘤,是来源于黑色素细胞的一类恶性肿瘤,常见于皮肤,亦见于黏膜、眼脉络膜等部位。人体长时间暴露在紫外线照射下,是黑色素瘤形成的主要原因。虽然黑色素瘤只占所有皮肤癌患者的5%,但近几十年增长迅速。黑色素瘤是皮肤肿瘤中恶性程度最高的瘤种,容易出现远处转移,且死亡率极高。
恶性黑色素瘤治疗方法主要有: 手术治疗、化疗、免疫治疗和靶向治疗。恶性黑色素瘤的恶性程度高,易转移,一旦确诊应尽快手术切除,因此外科手术切除病变是治疗该病的主要方法,但愈后差,容易复发,因此临床常用化疗方法治疗,虽然化疗药物曾一度作为恶性黑色素瘤脑转移治疗的标准方案,但现有化疗药物均未明显延长患者生存期,治疗效果有限。免疫治疗目前主要有抗细胞毒T 淋巴细胞相关蛋白4( CTLA4) 抗体治疗和抗程序性死亡-1( PD-1) 抗体治疗。但价格非常昂贵,无法普及。靶向治疗包括c-Kit 激酶抑制剂、B-RAF 抑制剂和MEK 抑制剂。2013 年美国国立综合癌症网络(NCCN) 治疗指南中将c-Kit 激酶抑制剂伊马替尼( imatinib) 作为Kit 突变的转移性黑色素瘤的指导用药。威罗菲尼(Vemurafenib)和卡比替尼(Cobimetinib) 分别作为B-RAF抑制剂和MEK 抑制剂,多靶点阻断细胞通路,降低了不良发应发生率,且价格适中,得到了很高的认可度,在临床上值得推广。
卡比替尼是美国Exelixis公司和Genentech公司联合研发的抗肿瘤新药,商品名为Cotellic,后由瑞士罗氏公司开发用于实体瘤治疗。该药属于口服小分子MEK 抑制剂,MEk是一种蛋白激酶,是RAS-RAF-MEK-ERK信号通路的一部分,该通路可促进细胞的***和存活,在人类癌症(包括黑色素瘤)中往往处于激活状态。卡比替尼能够选择性阻断MEK蛋白的活性,从而阻断其下游的信号通路传导。在体外和异种移植肿瘤模型的研究中,卡比替尼在肿瘤中浓度高且停留时间长,具有显著的抗肿瘤活性。
卡比替尼的化学名为 [3,4-二氟-2-[(2-氟-4-碘苯基)氨基]苯基][3-羟基-3-(2S)-2-哌啶基-1-氮杂环丁基]甲酮,分子式为C21H21F3IN3O2,分子量为531.31,结构式如下:
关于卡比替尼的化学合成方法已有多个专利以及文献报道。专利WO2007044515A1、WO2008076415A1、WO2008124085A3及文献Novel Carboxamide-Based Allosteric MEKInhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)(KDRice,N Aay,NK Anand,et al. Acs Medicinal Chemistry Letters, 2012, 3(5):416-421)均报道了如下的一种卡比替尼的合成路线。由于合成过程中需要多次手性拆分,合成步骤繁琐,收率低,从而限制了该合成方法的工业化前景。
专利WO2014059422公开了一种卡比替尼及其类似物的制备方法,该方法以手性氨基醇为手性诱导试剂,使其手性的获得更加方便和经济。其合成路线如下。但是,其反应条件过于苛刻(超低温-78oC,绝对无水无氧),原料价格昂贵,难以获得,强碱性试剂稳定性差限制了该条路线的工业化生产。
专利CN201510906811.2专利公布了卡比替尼的合成方法,该方法合成路线如下,以(2S)-2-哌啶为起始原料,经过多步合成得到目标产物,该条线路合成过程中涉及到氰化物,且合成路线长,综合收率低,合成过程具有高危险性、高污染性以及合成成本高的缺点。
专利CN201510121274.0公布了一种3-(哌啶-2-基)-氮杂环丁烷-3-醇的衍生物的合成方法,并以该化合物合成了卡比替尼,该方法以3-羰基-N-取代-环丁胺为起始原料,经过多步合成得到3-(哌啶-2-基)-氮杂环丁烷-3-醇的衍生物,该化合物经过进一步酰胺化、脱保护得到了目标产物卡比替尼。该条线路涉及到正丁基锂以及超低温(-50oC~-78oC)并且需要手性拆分,限制了该条路线的工业化放大应用。
专利CN201610361955.9公布了一种卡比替尼的合成方法,该方法将(R)-N-Boc-2-甲酸哌啶先后进行成盐反应、溴化反应、格氏反应、脱氨基反应、酰胺化反应、取代反应以及脱保护反应,得到卡比替尼。该条线路涉及到两次格式反应,反应操作繁琐,成本较高。
综上所述,目前针对卡比替尼的合成方法已有较多研究报道,但均存在诸多缺陷,如原料难得、合成步骤过长、产率较低拆分难度大、环境污染严重等。这些不利因素限制了卡比替尼的工业化生产,因此有必要开发起始原料便宜易得,合成工艺简洁易操作,合成过程经济环保,最终产物质量上乘的制备工艺。
发明内容
针对现有合成工艺存在的上述技术问题,本发明的目的是提供一种新的卡比替尼的制备方法。该方法原料便宜易得,反应条件温和,反应路线短,合成产率高、环境污染低的优点,适宜工业化生产。
为实现上述目的,本发明的技术方案如下:
一种卡比替尼的化学合成方法,包含如下步骤:
1):在有机碱存在下,化合物1与2-氟-4-碘苯胺反应得化合物2;
2):在Pd/C存在下,化合物2加氢脱保护得化合物3;
3):在缩合试剂存在下,化合物3经酰胺化反应得化合物4;
4):在过渡金属和/或过渡金属盐存在下,化合物4与2-卤代哌啶在溶剂中反应得卡比替尼。
作为本发明技术方案的进一步优化,上述步骤1)中所用有机碱为三乙胺、N,N-二异丙基乙胺、哌啶、吡啶中的任一种。
作为本发明技术方案的进一步优化,上述步骤1)中所用有机碱为所用有机碱为N,N-二异丙基乙胺。
作为本发明技术方案的进一步优化,上述步骤2)中所用Pd/C为10%Pd/C。
作为本发明技术方案的进一步优化,上述步骤3)中所用缩合试剂为EDCI/DMAP、PyBOP/DIEA、HOBt/DIC中的任一种。
作为本发明技术方案的进一步优化,上述步骤3)中所用缩合试剂为EDCI/DMAP。
作为本发明技术方案的进一步优化,上述步骤4)中所用2-卤代哌啶为(R)-2-氯哌啶、(R)-2-溴哌啶、(R)-2-碘哌啶中的任一种。
作为本发明技术方案的进一步优化,上述步骤4)中所用溶剂为水有机溶剂的混合溶剂;
步骤4)中所述过渡金属为锌、锡、铟、钐、钕中的任一种;步骤4)中所述过渡金属盐为二氯化锡、氯化铟、三氯化铟、二碘化钐中的任一种。
作为本发明技术方案的进一步优化,上述步骤4)中所用溶剂H2O和THF的混合溶剂;步骤4)中所述过渡金属为锌;所述过渡金属盐为三氯化铟。
作为本发明技术方案的进一步优化,前述卡比替尼的化学合成方法包含如下步骤:
1):将化合物1溶于DMF,搅拌溶清,加入2-氟-4-碘苯胺后, 0oC下搅拌逐滴加入N,N-二异丙基乙胺,加料完毕后置于60oC下反应6h,然后向反应液中加入HCl溶液搅拌,然后向反应液中加入乙酸乙酯,萃取,收集有机层,水层以乙酸乙酯萃取,合并有机层,无水硫酸镁干燥,过滤,减压蒸馏除去乙酸乙酯,得黄色油状液体,经柱层析纯化得化合物2;
2):将10% Pd/C和化合物2溶于无水乙醇中,室温条件下H2加压反应过夜,硅藻土过滤除去Pd/C,收集滤液,减压除去溶剂得化合物3;
3):将化合物3、3-氧代氮杂环丁烷盐酸盐和EDCI溶于DCM,然后加入DMAP,室温下搅拌,反应9h后以水淬灭,水层以DCM萃取,合并有机层,饱和食盐水洗,无水硫酸钠干燥,过滤,滤液浓缩后得黄色固体,将黄色固体溶于二氯甲烷,滴入正庚烷中,搅拌2h,有固体析出,过滤收集固体,干燥,得化合物4;
4):将化合物4、金属锌和饱和的NH4Cl水溶液混合,室温下搅拌,将(R)-2-溴哌啶溶于THF后逐滴加到上述含化合物4的反应液中,加料完毕室温条件下搅拌6 h~10h,过滤,收集滤液,乙酸乙酯萃取,收集有机层,水洗,饱和食盐水洗,无水硫酸钠干燥,过滤,减压蒸馏得到黄色油状液体,柱层析纯化得卡比替尼。
本发明技术方案所述的EDCI英文名:1-Ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride,中文名:1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐,CASNo. :25952-53-8;DMAP英文名:4-dimethylaminopyridine,中文名: 4-二甲氨基吡啶,CASNo. :1122-58-3;PyBOP英文名:Benzotriazol-1-yl-oxytripyrrolidinophosphonium 六氟磷酸苯并***-1-基-氧基三吡咯烷基磷 CAS号:128625-52-5;DIEA英文名:N-Ethyldiisopropylamine,中文名: N,N-二异丙基乙胺,CAS No. :7087-68-5;HOBt英文名:1-Hydroxybenzotriazole,中文名: 1-羟基苯并***,CAS No. :2592-95-2;DIC英文名:N, N-diisopropylcarbodiimide,中文名:N, N-二异丙基碳二亚胺,CAS No. :693-13-0;DMF英文名:N,N-dimethylformamide,中文名:N,N-二甲基甲酰胺,CAS No. :68-12-2;DCM英文名:Dichloromethane,中文名:二氯甲烷,CAS No. 75-09-2;THF英文名:Tetrahydrofuran ,中文名:四氢呋喃,CAS No. :109-99-9。上述试剂均为常用化学试剂,市场来源丰富。
通过与现有文献报的合成路线对比课件,本发明的卡比替尼合成路线以价格低廉易得的2,3,4-三氟苯甲酸苄酯为起始原料,经4步反应制得卡比替尼,且不需要额外的手性拆分步骤,合成步骤简洁产率高,合成条件温和反应易于控制,且未使用现有工艺常用的正丁基锂等毒性易***高污染高危险试剂,工艺路线安全性高,且属于环境友好型合成路线,利于产业化推广。
具体实施方式
以下结合具体实施例详细的解释本发明,该实施例仅用于解释本发明的技术方案,不能理解为限定本发明的保护范围。
实施例1 化合物2的合成
化合物1(26.6g,0.1mol,1.0eq)溶于DMF(200ml),搅拌溶清,加入2-氟-4-碘苯胺(26.07g,0.11mol,1.1eq),将其置于0oC的条件下,搅拌下逐滴加入N,N-二异丙基乙胺(69.3ml,0.5mol,5.0eq),加料完毕后,反应液置于60oC条件下反应6h,向反应液中加入0.5mol/L HCl溶液1000ml,搅拌10min,然后向反应液中加入乙酸乙酯500ml,萃取,收集有机层,水层以乙酸乙酯萃取(500ml×3),合并有机层,无水硫酸镁干燥2h,过滤,减压蒸馏除去乙酸乙酯,得到黄色油状液体,该黄色油状液体经柱层析纯化(200-300目硅胶为固定相,二氯甲烷:甲醇=4:1为洗提液)得化合物2(浅黄色油状液体)47.16g,产率为97.6%。化合物2的的磁共振图谱和质谱数据如下:
1H NMR(500Hz,CDCl3):δ 7.631-7.624(m, 1H), 7.472-7.461(m,2H), 7.382-7.369(m, 3H), 7.149-7.137(m,1H), 7.024-7.008(d, J=8.0Hz, 1H), 6.733-6.712(m, 1H),6.427-6.411(m, 1H), 5.11(s, 2H)。
13C NMR(500Hz,CDCl3):δ 167.512, 159.133, 153.275, 144.352, 141.643,136.585, 135.174, 129.303, 128.606, 127.047, 126.325, 126.6, 123.973,122.366, 111.784, 105.985, 91.249, 48.568。
MS(EI): 484.06(MH+)。
实施例2 化合物3的合成
在玻璃高压釜中在氩气下装入10% Pd/C(11.7g,4.4mmol,0.05eq,60.2%ww水,10%ww钯碳)和化合物2(42.7g,0.088mol,1.0eq)溶于200ml无水乙醇中,室温下H2加压(20~60psi)反应过夜,硅藻土过滤除去10% Pd/C,收集滤液,减压除去溶剂得到化合物3(黄色油状物)34.20g,收率98.8%。化合物3的的磁共振图谱和质谱数据如下:
1H NMR(500Hz,CDCl3):δ7.704-7.695(m,1H),7.198-7.185(m,1H), 7.064-7.054(m,1H), 6.815-6.802(m, 1H), 6.556-6.545(m, 1H)。
13C NMR(500Hz,CDCl3):δ 169.743, 160.221, 154.859, 147.094, 138.428,136.272, 130.569, 127.149, 125.144, 123.296, 112.885, 107.493, 94.195。
MS(EI): 393.98(MH+)。
实施例3 化合物4的合成
称取化合物3(33.07g,0.08mmol,1.0eq),3-氧代氮杂环丁烷盐酸盐(10.36g,0.088mmol,1.1eq),EDCI(18.41g,0.096mol,1.2eq)溶于DCM(300ml)中,然后加入DMAP(0.49g,4mmol,0.05eq),室温下搅拌反应9h,加入200ml水淬灭反应,水层DCM萃取(200ml×2),收集有机层,饱和食盐水洗后无水硫酸钠干燥。过滤,滤液浓缩后得到黄色固体,该固体溶于20ml二氯甲烷,滴入300ml正庚烷中,滴加完毕后,搅拌2h,有固体析出,过滤收集该固体,干燥,得化合物4(白色固体物质)32.85g,收率91.9%。化合物4的磁共振图谱和质谱数据如下:
1H NMR(500Hz,CDCl3):δ 7.628-7.614(m, 1H), 7.245-7.231(m,1H), 7.151-7.139(m, 1H), 6.864-6.850(m, 1H), 6.649-6.637(m, 1H), 4.932-4.919(m, 4H)。
13C NMR(500Hz,CDCl3):δ 191.894, 170.235, 160.862, 155.473, 148.659,139.032, 135.581, 131.011, 127.196, 125.894, 123.967, 120.051, 108.162,94.993, 59.159。
MS(EI): 447.01(MH+)。
实施例4 卡比替尼的合成
在反应瓶中加入化合物4 (26.8g,0.06mol,1.0eq),金属锌(9.75g,0.15mmol,2.5eq),饱和的NH4Cl水溶液(100ml)室温下搅拌。另称取(R)-2-溴哌啶(24.8g,0.15mol,2.5eq)溶于THF(100ml),氮气下逐滴加入到上述反应液中。加料完毕室温条件下搅拌7.2h,过滤,收集滤液,乙酸乙酯萃取(200ml×3),收集有机层,水洗(200ml×1),饱和食盐水洗(200ml×1)后无水硫酸钠干燥。过滤,滤液浓缩后得到黄色油状液体,该黄色油状液体经柱层析纯化(200-300目硅胶,乙酸乙酯:石油醚=1:2作为洗提液),得到卡比替尼(白色固体物质)29.38g,产率93.1%。卡比替尼的磁共振图谱和质谱数据如下:
1H NMR(500Hz,CDCl3):δ 7.674-7.663(m, 1H), 7.271-7.259(m, 1H), 7.137-7.122(m,1H), 6.649-6.633(m, 1H), 6.478-6.465(m, 1H), 4.432-4.415(m, 2H), 4.077-4.059 (m, 2H), 2.894-2.872(dd, J1=11.0Hz, J2=4.0Hz, 1H), 2.801-2.788(m, 1H),2.722-2.709(m, 1H), 1.602-1.467(m, 3H), 1.377-1.245(m, 2H), 1.154-1.140(m,1H)。
13C NMR(500Hz,CDCl3):δ 174.375, 162.133, 156.493, 149.479, 138.226,131.845, 128.596, 126.693, 124.747, 121.882, 120.004, 107.395, 97.652,74.389, 60.135, 57.328, 40.512, 30.119, 21.561, 19.852。
MS(EI): 532.14(MH+)。
实施例5 卡比替尼的合成
在反应瓶中加入化合物4 (10.7g,0.024mol,1.0eq),金属锌(3.12g,0.048mmol,2.0eq),三氯化铟即InCl3(10.60g,0.048mmol,2.0eq),然后向反应瓶中加入THF:H2O=1:1(体积比,90ml),室温下搅拌。另称取(R)-2-溴哌啶(9.84g,0.06mol,2.5eq)溶于THF(10ml),氮气保护下逐滴加入到上述反应液中。加料完毕后,室温下搅拌9.3h,过滤,收集滤液,乙酸乙酯萃取(100ml×3),收集有机层,水洗(100ml×1),饱和食盐水洗(100ml×1)后无水硫酸钠干燥。过滤,滤液浓缩后得到黄色油状液体,该黄色油状液体经柱层析纯化(200-300目硅胶,乙酸乙酯:石油醚=1:2作为洗提液),得到卡比替尼(白色固体物质)11.85g,产率88.5%。卡比替尼的磁共振图谱和质谱数据如下:
1H NMR(500Hz,CDCl3):δ 7.674-7.663(m, 1H), 7.271-7.259(m, 1H), 7.137-7.122(m,1H), 6.649-6.633(m, 1H), 6.478-6.465(m, 1H), 4.432-4.415(m, 2H), 4.077-4.059 (m, 2H), 2.894-2.872(dd, J1=11.0Hz, J2=4.0Hz, 1H), 2.801-2.788(m, 1H),2.722-2.709(m, 1H), 1.602-1.467(m, 3H), 1.377-1.245(m, 2H), 1.154-1.140(m,1H)。
13C NMR(500Hz,CDCl3):δ 174.375, 162.133, 156.493, 149.479, 138.226,131.845, 128.596, 126.693, 124.747, 121.882, 120.004, 107.395, 97.652,74.389, 60.135, 57.328, 40.512, 30.119, 21.561, 19.852。
MS(EI): 532.14(MH+)。
实施例6 卡比替尼的合成
在反应瓶中加入化合物4 (13.2g,0.0295mol,1.0eq),金属锌(4.81g,0.074mmol,2.5eq),饱和的NH4Cl水溶液(50ml),室温条件下搅拌。另称取(R)-2-碘哌啶(15.61g,0.074mol,2.5eq)溶于THF(50ml),氮气保护下逐滴加入到上述反应液中。加料完毕后室温下搅拌8.6h,过滤,收集滤液,乙酸乙酯萃取(100ml×3),收集有机层,水洗(100ml×1),饱和食盐水洗(100ml×1)后无水硫酸钠干燥。过滤,滤液浓缩后得到黄色油状液体,该黄色油状液体经柱层析纯化(200-300目硅胶,乙酸乙酯:石油醚=1:2作为洗提液),得到卡比替尼(白色固体物质)14.01g,产率89.1%。卡比替尼的磁共振图谱和质谱数据如下:
1H NMR(500Hz,CDCl3):δ 7.674-7.663(m, 1H), 7.271-7.259(m, 1H), 7.137-7.122(m,1H), 6.649-6.633(m, 1H), 6.478-6.465(m, 1H), 4.432-4.415(m, 2H), 4.077-4.059 (m, 2H), 2.894-2.872(dd, J1=11.0Hz, J2=4.0Hz, 1H), 2.801-2.788(m, 1H),2.722-2.709(m, 1H), 1.602-1.467(m, 3H), 1.377-1.245(m, 2H), 1.154-1.140(m,1H)。
13C NMR(500Hz,CDCl3):δ 174.375, 162.133, 156.493, 149.479, 138.226,131.845, 128.596, 126.693, 124.747, 121.882, 120.004, 107.395, 97.652,74.389, 60.135, 57.328, 40.512, 30.119, 21.561, 19.852。
MS(EI): 532.14(MH+)。
实施例7 卡比替尼的合成
在反应瓶中加入化合物4 (9.5g,0.021mol,1.0eq),金属锌(3.46g,0.053mmol,2.5eq),饱和的NH4Cl水溶液(40ml),室温下搅拌。另称取(R)-2-溴哌啶(8.73g,0.053mol,2.5eq)溶于甲苯即PhCH3(40ml),氮气保护下逐滴加入到上述反应液中。加料完毕后,室温下搅拌6.7h,过滤,收集滤液,乙酸乙酯萃取(80ml×3),收集有机层,水洗(80ml×1),饱和食盐水洗(80ml×1)后无水硫酸钠干燥。过滤,滤液浓缩后得到黄色油状液体,该黄色油状液体经柱层析纯化(200-300目硅胶,乙酸乙酯:石油醚=1:2作为洗提液),得到卡比替尼(白色固体物质)10.21g,产率90.2%。卡比替尼的磁共振图谱和质谱数据如下:
1H NMR(500Hz,CDCl3):δ 7.674-7.663(m, 1H), 7.271-7.259(m, 1H), 7.137-7.122(m,1H), 6.649-6.633(m, 1H), 6.478-6.465(m, 1H), 4.432-4.415(m, 2H), 4.077-4.059 (m, 2H), 2.894-2.872(dd, J1=11.0Hz, J2=4.0Hz, 1H), 2.801-2.788(m, 1H),2.722-2.709(m, 1H), 1.602-1.467(m, 3H), 1.377-1.245(m, 2H), 1.154-1.140(m,1H)。
13C NMR(500Hz,CDCl3):δ 174.375, 162.133, 156.493, 149.479, 138.226,131.845, 128.596, 126.693, 124.747, 121.882, 120.004, 107.395, 97.652,74.389, 60.135, 57.328, 40.512, 30.119, 21.561, 19.852。
MS(EI): 532.14(MH+)。
由实施例可以看出,本发明的技术方案合成步骤简洁条件温和各步骤及总产率均较高,且未使用高污染催化剂和高***危险的化学反应,适于大规模工业化生产。
Claims (10)
1.一种卡比替尼的化学合成方法,其特征在于,包含如下步骤:
1):在有机碱存在下,化合物1与2-氟-4-碘苯胺反应得化合物2;
2):在Pd/C存在下,化合物2加氢脱保护得化合物3;
3):在缩合试剂存在下,化合物3经酰胺化反应得化合物4;
4):在过渡金属和/或过渡金属盐存在下,化合物4与2-卤代哌啶在溶剂中反应得卡比替尼。
2.根据权利要求1所述的卡比替尼的化学合成方法,其特征在于,步骤1)中所用有机碱为三乙胺、N,N-二异丙基乙胺、哌啶、吡啶中的任一种。
3.根据权利要求2所述的卡比替尼的化学合成方法,其特征在于,步骤1)中所用有机碱为N,N-二异丙基乙胺。
4.根据权利要求1所述的卡比替尼的化学合成方法,其特征在于,步骤2)中所用Pd/C为10%Pd/C。
5.根据权利要求1所述的卡比替尼的化学合成方法,其特征在于,步骤3)中所用缩合试剂为EDCI/DMAP、PyBOP/DIEA、HOBt/DIC中的任一种。
6.根据权利要求5所述的卡比替尼的化学合成方法,其特征在于,步骤3)中所用缩合试剂为EDCI/DMAP。
7.根据权利要求1所述的卡比替尼的制备方法,其特征在于,步骤4)中所用2-卤代哌啶
为(R)-2-氯哌啶、(R)-2-溴哌啶、(R)-2-碘哌啶中的任一种。
8.根据权利要求1所述的卡比替尼的化学合成方法,其特征在于,步骤4)中所用溶剂为水有机溶剂的混合溶剂;步骤4)中所述过渡金属为锌、锡、铟、钐、钕中的任一种;步骤4)中所述过渡金属盐为二氯化锡、氯化铟、三氯化铟、二碘化钐中的任一种。
9.根据权利要求1所述的卡比替尼的化学合成方法,其特征在于,步骤4)中所用溶剂为H2O和THF的混合溶剂;步骤4)中所述过渡金属为锌;步骤4)中所述过渡金属盐为三氯化铟。
10.根据权利要求1至9所述的卡比替尼的化学合成方法,其特征在于,包含如下步骤:
1):将化合物1溶于DMF,搅拌溶清,加入2-氟-4-碘苯胺后, 0oC下搅拌逐滴加入N,N-二异丙基乙胺,加料完毕后置于60oC下反应6h,然后向反应液中加入HCl溶液搅拌,然后向反应液中加入乙酸乙酯,萃取,收集有机层,水层以乙酸乙酯萃取,合并有机层,无水硫酸镁干燥,过滤,减压蒸馏除去乙酸乙酯,得黄色油状液体,经柱层析纯化得化合物2;
2):将10% Pd/C和化合物2溶于无水乙醇中,室温条件下H2加压反应过夜,硅藻土过滤除去Pd/C,收集滤液,减压除去溶剂得化合物3;
3):将化合物3、3-氧代氮杂环丁烷盐酸盐和EDCI溶于DCM,然后加入DMAP,室温下搅拌,反应9h后以水淬灭,水层以DCM萃取,合并有机层,饱和食盐水洗,无水硫酸钠干燥,过滤,滤液浓缩后得黄色固体,将黄色固体溶于二氯甲烷,滴入正庚烷中,搅拌2h,有固体析出,过滤收集固体,干燥,得化合物4;
4):将化合物4、金属锌和饱和的NH4Cl水溶液混合,室温下搅拌,将(R)-2-溴哌啶溶于THF后逐滴加到上述含化合物4的反应液中,加料完毕室温条件下搅拌6 h~10h,过滤,收集滤液,乙酸乙酯萃取,收集有机层,水洗,饱和食盐水洗,无水硫酸钠干燥,过滤,减压蒸馏得到黄色油状液体,柱层析纯化得卡比替尼。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710105737.3A CN106866624B (zh) | 2017-02-27 | 2017-02-27 | 一种卡比替尼的化学合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710105737.3A CN106866624B (zh) | 2017-02-27 | 2017-02-27 | 一种卡比替尼的化学合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106866624A true CN106866624A (zh) | 2017-06-20 |
CN106866624B CN106866624B (zh) | 2017-12-26 |
Family
ID=59167719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710105737.3A Expired - Fee Related CN106866624B (zh) | 2017-02-27 | 2017-02-27 | 一种卡比替尼的化学合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106866624B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109232531A (zh) * | 2018-10-26 | 2019-01-18 | 安庆奇创药业有限公司 | 一种卡比替尼的制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
CN101365676A (zh) * | 2005-10-07 | 2009-02-11 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
WO2009036020A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
WO2014078669A1 (en) * | 2012-11-15 | 2014-05-22 | Duquesne University Of The Holy Ghost | Carboxylic acid ester prodrug inhibitors of mek |
WO2015038743A1 (en) * | 2013-09-11 | 2015-03-19 | The Administrators Of The Tulane Educational Fund | Novel anthranilic amides and the use thereof |
CN104725352A (zh) * | 2015-03-19 | 2015-06-24 | 上海皓元生物医药科技有限公司 | 一种3-(哌啶-2-基)-氮杂环丁烷-3-醇的衍生物的合成方法及其用途 |
CN105330643A (zh) * | 2015-12-09 | 2016-02-17 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
CN106045969A (zh) * | 2016-05-27 | 2016-10-26 | 湖南欧亚生物有限公司 | 一种卡比替尼的合成方法 |
-
2017
- 2017-02-27 CN CN201710105737.3A patent/CN106866624B/zh not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101365676A (zh) * | 2005-10-07 | 2009-02-11 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
WO2009036020A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
WO2014078669A1 (en) * | 2012-11-15 | 2014-05-22 | Duquesne University Of The Holy Ghost | Carboxylic acid ester prodrug inhibitors of mek |
WO2015038743A1 (en) * | 2013-09-11 | 2015-03-19 | The Administrators Of The Tulane Educational Fund | Novel anthranilic amides and the use thereof |
CN104725352A (zh) * | 2015-03-19 | 2015-06-24 | 上海皓元生物医药科技有限公司 | 一种3-(哌啶-2-基)-氮杂环丁烷-3-醇的衍生物的合成方法及其用途 |
CN105330643A (zh) * | 2015-12-09 | 2016-02-17 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
CN106045969A (zh) * | 2016-05-27 | 2016-10-26 | 湖南欧亚生物有限公司 | 一种卡比替尼的合成方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109232531A (zh) * | 2018-10-26 | 2019-01-18 | 安庆奇创药业有限公司 | 一种卡比替尼的制备方法 |
CN109232531B (zh) * | 2018-10-26 | 2020-06-16 | 安庆奇创药业有限公司 | 一种卡比替尼的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106866624B (zh) | 2017-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105461695B (zh) | 嘧啶或三嗪衍生物及其制备方法和用途 | |
CN109293657B (zh) | 一种α-咔啉酮类化合物及其制备方法和应用 | |
CN108947949B (zh) | 抗焦虑氘代化合物及其医药用途 | |
CN110305166B (zh) | 一种以姜黄素衍生物为配体的钌(ii)配合物及其制备方法和应用 | |
CN106866624B (zh) | 一种卡比替尼的化学合成方法 | |
CN101638389B (zh) | 一种含萘酰亚胺结构的多胺衍生物及其制备方法和应用 | |
KR20180128456A (ko) | 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물 | |
CN110283162B (zh) | 一种表皮生长因子受体抑制剂及其应用 | |
CN107573336B (zh) | 苯并杂环-甲酰胺-吡啶酮衍生物及其制备方法和用途 | |
CN112175014B (zh) | 一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途 | |
CN110305067A (zh) | 一种抗癌药物达卡巴嗪的优化合成工艺 | |
CA2040123A1 (en) | Ethylene-substituted phenylalkylethylenediamine-platinum (ii or iv) derivatives and phenylalkylethylenediamines | |
CN103435554A (zh) | 2-苯氨基苯并咪唑类化合物及其用途 | |
CN108017639B (zh) | Ido抑制剂及其制备方法和应用 | |
Wang et al. | Highly asymmetric dihydroxylation of 1-aryl-1′-pyridyl alkenes | |
CN102746226A (zh) | 吖啶衍生物及其制备方法和应用 | |
CN110551057B (zh) | 手性3,3-二取代氧化吲哚衍生物及其合成方法和应用 | |
CN115433203A (zh) | 一种胺氟化莪术醇衍生化合物及及其应用与制备方法 | |
CN102010348A (zh) | 水杨酰胺酯类衍生物、制备方法及其应用 | |
CN114276328B (zh) | 作为小分子免疫抑制剂的化合物、其制备方法及其应用 | |
CN114436925B (zh) | 间二苯酚醚类化合物及其制备方法与应用 | |
CN105985320B (zh) | 苄基酞嗪化合物及其制备方法和用途 | |
CN104672136A (zh) | 1-取代菲基-n-烷基(酰基)-6,7-二甲氧基-1,2,3,4-四氢异喹啉衍生物及其制备方法和用途 | |
CN113582971B (zh) | 一种小分子免疫抑制剂、其制备方法及其应用 | |
CN103242244B (zh) | 一种卡奈替尼的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171226 |